An observational study in Parkinson Disease, sponsored by Neuron23 Inc.. Terminated at 8 sites in 4 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2023-10-30.
Sponsored by Neuron23 Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,650 studies in Parkinson Disease with a site in United States — 305 open to participants now, 387 under way, 7 of them phase 3. Parkinson Disease · United States.
Among the 1,650 studies in Parkinson Disease with a site in United States, this one is the 205th largest by enrollment of the 379 observational ones that give a count, is one of 104 that started in 2021, is one of 381 observational ones, and was the 1,168th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →305 of the 1,650 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:
The Cleveland Clinic · Sites in United States
Ages 18+
University of Colorado, Denver · Sites in United States
Ages 45–75
University of Minnesota · Sites in United States
Ages 18+
Hoffmann-La Roche · Sites in United States, China, Ireland and 2 more countries
Ages 40–85
VA Office of Research and Development · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,650 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 226 · Phase 2 304 · Phase 3 145 · Phase 4 75
First in 1991; this study’s year is marked. 104 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 65 is below the median of 96 across 1,088 observational studies indexed under Parkinson Disease.
Median enrollment 36 across the 1,257 interventional studies, 78 across the 379 observational. Of the 1,140 that completed or were terminated, 435 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
470 of 1,650 have an industry lead sponsor. The 10 most frequent:
Neuron23 Inc. is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Neuron23 Inc. has 2 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
137 of the studies in Parkinson Disease with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06976268Phase 3Biohaven Therapeutics Ltd.A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease | 2027-08 |
| NCT06098612Massachusetts General HospitalPET Imaging Evaluation of [11C]SY08 | 2026-11 |
| NCT06489483University of Texas Southwestern Medical CenterAction Regulation Behavioral | 2026-11 |
| NCT06773962TrueBinding, Inc.A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease | 2026-11-28 |
| NCT06447207Colorado State UniversityOccupational Therapy Led Social Prescription for People With Parkinson Disease | 2026-11-30 |
Add all 137 to your calendar (.ics) → With an account.
Among the 1,650 studies in Parkinson Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to collect, analyze and preserve biospecimens from patients with or without LRRK2-associated Parkinson's Disease for the purpose of discovering and developing new treatments and novel biomarkers.
Parkinson's patients will be recruited across this multi-center, global clinical study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with a G2019S mutation
Patients with a low burden of genetic modifiers
Patients with a high burden of genetic modifiers
Genetic Marker
Test for LRRK2 mutations in Parkinson disease patients; identifying patients with potential genetic modifiers
Time frame: 1 day
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2021 to primary completion in Jun 2023, 24 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Neuron23 Inc.